Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Cardiogeni's share price for the quarter that ended in . 20 was £. Cardiogeni's Shares Outstanding (EOP) for the quarter that ended in . 20 was 0.00 Mil. Therefore, Cardiogeni's market cap for the quarter that ended in . 20 was £ Mil.
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cardiogeni's Enterprise Value for Today is £5.97 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Cardiogeni Market Cap Related Terms
Cardiogeni Market Cap Historical Data
* Premium members only.
The historical data trend for Cardiogeni's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiogeni Market Cap Chart
Cardiogeni Annual Data
Trend
Market Cap
Cardiogeni Semi-Annual Data
Market Cap
AQSE:CGNI vs : Market Cap Comparison
For the Biotechnology subindustry, Cardiogeni's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiogeni Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiogeni's Market Cap distribution charts can be found below:
* The bar in red indicates where Cardiogeni's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Cardiogeni's Market Cap for the fiscal year that ended in . 20 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiogeni (AQSE:CGNI) has a Market Cap of £5.97 Mil as of Sep. 11, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cardiogeni and its competitors.
Is Cardiogeni's Market Cap too high?
Cardiogeni's current Market Cap is £5.97 Mil.
How does Cardiogeni's Market Cap compare to ?
Cardiogeni's Market Cap of £5.97 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 118.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 118.46, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cardiogeni and its competitors. For the Biotechnology industry, the median Market Cap is 118.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiogeni's current Market Cap is £5.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiogeni stock overvalued right now?
Cardiogeni (AQSE:CGNI) has a current Market Cap of £5.97 Mil. The current Market Cap is £5.97 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Cardiogeni (AQSE:CGNI), the current Market Cap is £5.97 Mil as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiogeni PLC is engaged in the development and commercialisation of a portfolio of novel cellular medicines for heart failure. The Company focuses on the development and commercialisation of novel cellular medicines targeting early- and mid-stage heart failure. Its strategic priority is to complete a pivotal Phase 2b/3 study and obtain first market approval for its product, CLXR-001, in a suitable jurisdiction, and then establish strategic funding and collaboration agreements to develop and commercialise the product in the US, EU, Japan, and other jurisdictions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQSE:CGNI has been successfully added to your 
